Maiwei Bio-B (02493): Clinical trial application for 9MW5211 injection for vitiligo indications approved

Zhitongcaijing · 2d ago

Zhitong Financial App News, Maiwei Bio-B (02493) announced that recently, the company received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the clinical trial application for 9MW5211 injections for vitiligo indications was approved. Previously, its clinical trial application for inflammatory bowel disease (IBD) indications had been approved by the National Drug Administration and FDA approval respectively. Clinical trial applications for multiple sclerosis (MS) and type 1 diabetes (T1DM) indications have been obtained from the China Drug Administration Approval; The company is also actively promoting clinical trial applications for various other indications, and clinical trial applications for some indications have been accepted by the State Drug Administration.